Impact of direct-acting antivirals on leukocytic DNA telomere length in hepatitis C virus-related hepatic cirrhosis
Authors:
- 1 April 2019
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 31 (4) , 494-498
Abstract
Background: Direct-acting antiviral (DAAs) represent advancement in the management of hepatitis C virus (HCV)-related hepatic cirrhosis. A high proportion of patients achieve a sustained virologic response; eradication of HCV is coupled with a decreased risk of hepatocellular carcinoma. Recent evidence suggests that shortening of the DNA telomere may be linked to cellular senescence as well as predisposition to malignant transformation. Objective: This study aimed to assess pretreatment leukocytic DNA telomere length in HCV-related cirrhosis and post viral eradication using DAAs. Patients and methods: This study included 24 patients with HCV-related cirrhosis, Child–Pugh A. Whole-blood samples were obtained from patients before treatment and 12 weeks after the end of treatment, as well as from 24 healthy controls. Terminal restriction fragment, corresponding to telomere length, was measured using a nonradioactive Southern blot technique, detected by chemiluminescence. Results: DNA telomere length was significantly shorter before treatment compared with 12 weeks after end of treatment in HCV-related cirrhotic patients. Also, it was significantly shorter in patients before treatment compared with healthy individuals. Conclusion: Telomere elongation in blood leukocytes can be considered a marker of recovery of inflammation after DAAs-induced HCV eradication. Still, the possibility of activation by cancer initiation cannot be excluded.Keywords
This publication has 30 references indexed in Scilit:
- Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolutionJournal of Hepatology, 2016
- Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antiviralsJournal of Hepatology, 2016
- Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohortsJournal of Hepatology, 2016
- Direct antiviral agents and risk for HCC early recurrence: Much ado about nothingJournal of Hepatology, 2016
- Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapyJournal of Hepatology, 2016
- Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialThe Lancet Infectious Diseases, 2016
- Should surveillance for liver cancer be modified in hepatitis C patients after treatment‐related cirrhosis regression?Liver International, 2016
- New Hepatitis C Therapies: The Toolbox, Strategies, and ChallengesGastroenterology, 2014
- Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinomaHepatology, 2013
- Role of telomeres and telomerase in cancerSeminars in Cancer Biology, 2011